SRC and colorectal carcinoma: To this end, the objective of this study was to elucidate the role of SRC in BRAFV600E CRC cell lines and to evaluate the antitumor activity of dasatinib (an orally bioavailable potent inhibitor of SRC (SRCi)) in combination with BRAFi (vemurafenib and encorafenib) using in vitro and in vivo models.